Olumiant (baricitinib) / Incyte, Eli Lilly - LARVOL DELTA

A hydrophilic interaction UPLC-MS/MS quantitative method for the quantification of saracatinib in the human liver microsome matrix and its application in in vitro metabolic stability assessment. (PubMed, Anal Methods) - "SRB and baricitinib, used as an internal standard (IS), were isolated from HLMs using protein precipitation with acetonitrile (ACN) as the extracting agent. The metabolic stability parameters, including the in vitro half-life (t1/2) and intrinsic clearance (Clint) of SRB, were assessed at 17.24 min and 47.02 mL min-1 kg-1, respectively. In silico research indicated that slight structural modifications to the N-methyl piperazine ring in the drug design may enhance metabolic stability and safety compared with those of SRB."

Journal • Preclinical • ABL1 • BCR

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Stanford University | Trial completion date: Apr 2028 ➔ Dec 2028 | Initiation date: Jul 2025 ➔ Apr 2026 | Trial primary completion date: Jan 2028 ➔ Jul 2028

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Sarcoidosis

JAKUVEITE: Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (clinicaltrials.gov) - P3 | N=33 | Not yet recruiting | Sponsor: University Hospital, Rouen | Trial completion date: Aug 2026 ➔ Aug 2029 | Trial primary completion date: Aug 2023 ➔ Aug 2029

Trial completion date • Trial primary completion date • Ocular Inflammation • Ophthalmology • Uveitis

TREATMENT OF SOLID FACIAL EDEMA USING SYSTEMIC BIOLOGICS AND JAK INHIBITORS: A SYSTEMATIC REVIEW (WRMC 2026) - "Treatments included abrocitinib (n=3), omalizumab (n=3), tofacitinib (n=2), and baricitinib (n=1). Biologics and JAKi appear to be safe and effective for treatment-refractory SFE, with outcomes ranging from substantial improvement to complete remission. Although evidence is limited to small series and case reports, these findings suggest a role for targeted immunomodulation in SFE management. Larger prospective studies are needed to confirm efficacy, assess long-term safety, and establish clinical guidelines."

Review • Dermatology • Hematological Disorders • Immunology • Novel Coronavirus Disease • Pruritus • Thrombocytopenia

HAPLOIDENTICAL DONOR-DERIVED CAR-T CELLS CO-INFUSED WITH THE ALLOGENIC GRAFT ON THE PLATFORM OF T CELL DEPLETION OR POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH ADVANCED B-CELL NEOPLASMS (EBMT 2026) - "In the PtCy group GVHD prophylaxis included abatacept, vedolizumab and CsA or baricitinib There was no suspected conflict between the graft and CAR-T cells. Our early experience suggests that allogenic CAR-T cells can be safely infused simultaneously with the HSC graft both on the platform of T cell depletion and PtCy-based GVHD prophylaxis. The infusions did not compromise engraftment and GvHD control, while specific CAR-T toxicity was mild and manageable. We have documented CAR-T expansion and persistence."

CAR T-Cell Therapy • Clinical • Metastases • Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • CCR2 • CD22

Lung Inflammation and Acute Lung Injury Predict Neurological Outcome Following Intracerebral Hemorrhage and Are Mitigated by JAK Inhibition (ISC 2026) - "Baricitinib reduced inflammatory activity of neutrophils and JAK signaling in BALF and blood, indicating compartment-specific immunomodulation.Conclusion Combined cohort analysis and single-cell profiling revealed early neutrophil activation as an initiator of lung inflammation and acute lung injury after ICH. JAK inhibition reduced inflammatory activity of neutrophils and acute lung inflammation, suggesting JAK inhibition as a promising strategy to mitigate pulmonary complications following ICH."

Late-breaking abstract • Acute Lung Injury • Cerebral Hemorrhage • Hematological Disorders • Infectious Disease • Inflammation • Pneumonia • Respiratory Diseases

PALETTE: Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (clinicaltrials.gov) - P2 | N=2000 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Phase classification: P3 ➔ P2 | Trial completion date: Apr 2032 ➔ May 2031 | Trial primary completion date: May 2029 ➔ Jun 2028

Pan tumor • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Septic Shock

Cardiovascular Adverse Events of JAK vs. TNF Inhibitors using the Korean Pharmacovigilance Database. (PubMed, Cardiology) - "Methods Adverse event (AE) reports between January 1, 2015 and December 31, 2020 of JAK-Is (tofacitinib or baricitinib) or TNF-Is (adalimumab, etanercept, or golimumab) were included. These trends were particularly notable in women (CVEs: ROR: 7.52, 95% CI: 3.06-18.47) and in patients over 50 years old (CVEs: ROR: 5.01, 95% CI: 2.02-12.43). Conclusion This disproportionality analysis using a national pharmacovigilance database identified reporting signals for total CVEs with JAK-Is compared to TNF-Is; in particular, a significant signal for thrombosis was observed."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Thrombosis

Stand UP to Rheumatoid Arthritis (SUPRA) (clinicaltrials.gov) - P=N/A | N=75 | Recruiting | Sponsor: Marie Hudson, MD | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

JAK1 or JAK1/2 inhibitors in Drug Reaction with Eosinophilia and Systemic Symptoms: A case series. (PubMed, Clin Exp Dermatol) - "Six patients (median age 35 years; five females) received baricitinib or abrocitinib with CS between July 2023 and June 2024. No severe adverse events occurred, including in patients with pancytopenia or hepatic dysfunction. JAK inhibitors appear effective and well-tolerated in promoting CS tapering in refractory DRESS, suggesting larger controlled studies are needed."

Journal • Dermatology • Eosinophilia • Hematological Disorders • Hepatology • Immunology • Liver Failure • Pruritus • IL5

Study protocol for neuroimaging using 7 T MRI in the investigation of baricitinib for reduction of HIV in the CNS: a randomized placebo-controlled trial. (PubMed, BMC Med Imaging) - No abstract available

Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Janus Kinase Inhibitors for the Treatment of Prurigo Nodularis: A Systematic Review of 211 Patients. (PubMed, J Dermatol) - "Agents evaluated included upadacitinib, tofacitinib, abrocitinib, and baricitinib. Limitations include small sample sizes, predominance of uncontrolled and observational designs, heterogeneity of outcomes, and limited long-term safety data. Current evidence suggests JAK-Is are highly effective and generally well tolerated for PN, warranting larger randomized controlled trials with extended follow-up."

Journal • Review • Dermatology • Dyslipidemia • Immunology • Infectious Disease • Metabolic Disorders • Prurigo Nodularis

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. (PubMed, Cureus) - "Only studies involving adult patients with RA treated by approved JAKis (baricitinib, tofacitinib, upadacitinib, peficitinib, and filgotinib) were included...JAKis consistently demonstrated superior responses compared with placebo and methotrexate, with higher American College of Rheumatology 20% response rates, improved disease activity scores, reduced radiographic progression, and enhanced patient-reported outcomes. In head-to-head comparisons, baricitinib and upadacitinib demonstrated advantages over adalimumab across multiple efficacy domains...Nonetheless, their use requires individualized, risk-stratified decision-making, with particular caution in patients at elevated cardiovascular or malignancy risk. Ongoing long-term studies and real-world data remain essential to further define their benefit-risk profile and optimize their integration into personalized RA care."

Journal • Review • Cardiovascular • Herpes Zoster • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Varicella Zoster

Management of Community-Acquired Pneumonia in Adults - Argentine Society of Infectious Diseases (PubMed, Medicina (B Aires)) - "The benefit of neuraminidase inhibitors for influenza is of low certainty and relatively marginal. Treatments that have had an impact on reducing mortality from severe-critical COVID-19 are corticosteroids, IL-6 receptor blockers, and baricitinib."

Journal • Review • Critical care • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL6

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report. (PubMed, Mult Scler J Exp Transl Clin) - "Despite their therapeutic benefits, inflammatory demyelinating diseases of the central nervous system (CNS) have been reported in association with JAKi treatment, most previously involving tofacitinib in patients with rheumatoid arthritis. We report the first case of a CNS inflammatory demyelinating disease that was possibly exacerbated by baricitinib, underscoring the need for heightened clinical vigilance and close monitoring of patients receiving JAKi therapy."

Journal • CNS Disorders • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR) - P=N/A | N=60 | Recruiting | Sponsor: The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2025 ➔ Nov 2025

Enrollment open • Trial initiation date • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Baricitinib in the treatment of adults with PG: an open-label pilot trial. (PubMed, J Invest Dermatol) - No abstract available

Journal • Pyoderma Gangrenosum

Real-world experience of JAK Inhibitors in eyebrow regrowth for alopecia areata: a retrospective single-center study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Retrospective data • Alopecia • Immunology

Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews. (PubMed, Cureus) - "Using recent evidence syntheses in alopecia areata, we show how inclusion of small, underpowered dose strata and regimens that never advanced to pivotal trials or were not pursued for regulatory approval (for example, deuruxolitinib 4 mg twice‑daily {BID}, deuruxolitinib 12 mg BID, and ritlecitinib 200 mg loading doses) can distort pooled efficacy and safety estimates, elevate unapproved regimens in rankings, and invite inappropriate causal inferences. We outline key methodological safeguards and offer concrete recommendations as follows: prespecify exclusion or planned sensitivity analyses for unapproved doses, transparently report approval status and relevant regulatory actions (for example, clinical holds) alongside pooled safety estimates, avoid causal attributions from small strata and present uncertainty appropriately, and report sensitivity analyses that omit unapproved doses. Implementing these practices preserves the statistical advantages of meta-analysis..."

Journal • Alopecia • Immunology

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis (clinicaltrials.gov) - P4 | N=60 | Active, not recruiting | Sponsor: Tongji Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2023 ➔ Nov 2026 | Trial primary completion date: Mar 2023 ➔ Aug 2026

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Scleroderma • Systemic Sclerosis

Switching between Janus kinase inhibitors for treatment of alopecia areata: A Multi-Center Retrospective Review. (PubMed, J Am Acad Dermatol) - "Switching between JAKis appears to be a viable strategy for severe AA patients, especially those responding to prior JAKi. Prior response may help guide treatment sequencing."

Journal • Retrospective data • Alopecia • Immunology

Severe Hepatic Adverse Event Induced by Anti-HER2 Therapy in Breast Cancer: A Case of Successful Immunotherapy With Baricitinib. (PubMed, ACR Open Rheumatol) - No abstract available

Adverse events • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. (PubMed, J Clin Med) - "This case highlights the potential efficacy of JAK inhibition in managing JDM with a high IFN signature and supports a mechanism-based, interferon-targeted treatment approach, in line with emerging evidence in refractory JDM. Further studies are warranted to define the role of JAK inhibitors in the treatment of JDM."

Journal • Dermatomyositis • Immunology • Inflammation • Myositis • IFIH1

Assessment of Apalutamide Metabolic Stability in HLMs Matrix Using a Sensitive and Fast UPLC-MS/MS Method: In Silico Screening for Toxicity Alerts and Metabolic Lability. (PubMed, Biomed Chromatogr) - "An isocratic mobile phase system with a C18 column segregated APD and baricitinib (BCB as internal standard). APD's in vitro half-life (t1/2) and intrinsic clearance (Clint) were 25.57 min and 31.7 mL/min/kg, respectively. These in silico data propose that APD derivatives with changes in N-methyl moiety might reveal altered metabolic lability; this requires experimental verification."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Deuruxolitinib for Alopecia Areata. (PubMed, Skin Therapy Lett) - "Deuruxolitinib is the third oral JAK inhibitor approved for the treatment of severe AA, the others being baricitinib and ritlecitinib. Deuruxolitinib's mechanism of action, clinical efficacy, and safety profile in the treatment of AA are reviewed."

Journal • Review • Alopecia • Immunology • CD8 • IFNG • IL15